首页> The Lancet. Rheumatology> Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.

导出 LinkOut

翻译打印收藏纠错

第一作者： Giulio,Cavalli

第一单位： Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.;Vita-Salute San Raffaele University, Milan, Italy.

作者： Giulio,Cavalli ^[1] ; Alessandro,Larcher ^[2] ; Alessandro,Tomelleri ^[1] ; Lorenzo,Dagna ^[1]

作者单位： Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.;Vita-Salute San Raffaele University, Milan, Italy. ^[1] Unit of Urology, Division of Experimental Oncology, URI-Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. ^[2]

DOI 10.1016/S2665-9913(21)00066-7

PMID 33782670

发布时间 2021-04-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The Lancet. Rheumatology

2021年3卷4期

e248-e249页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

The Lancet. Rheumatology

2021年3卷4期

e248-e249页

检索历史清除

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.

The Lancet. Rheumatology

相似文献

同项目论文

The Lancet. Rheumatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.

The Lancet. Rheumatology

相似文献

同项目论文

The Lancet. Rheumatology

相关期刊

检索历史清除